1 Title: Vaccination status and re-infection among COVID patients admitted in COVID High

2 Dependency Unit (HDU) of a tertiary hospital in Eastern Nepal: A cross-sectional study

3 Short title: Vaccination status and re-infection among COVID patients

- 4 Sujan Kafle¹, Varsha Chhetri¹, Joshan Lal Bajracharya², Lenish Pokharel¹, Suyash Dawadi¹, Ujwal Basnet¹,
- 5 Shreya Dhungana¹, Durga Neupane¹
- 6

- 1. B.P. Koirala Institute of Health Sciences, Dharan, Nepal
- 8 2. Consultant Anesthesiologist, Department of Anesthesiology and Critical Care, Provincial 9 Hospital Bhadrapur, Jhapa
- 10 Authors:
- Sujan Kafle (Corresponding author) 11
- 12 Email: sujank79@gmail.com
- 13 Varsha Chhetri
- 14 Email: chhetrivarsha16@gmail.com
- 15 Dr. Joshan Lal Bajracharya
- 16 Email: bajracharyajoshanlal@gmail.com
- 17 Lenish Pokharel
- 18 Email: lenishpokharel@gmail.com
- 19 Suyash Dawadi
- 20 Email: suyash.dawadi@gmail.com
- 21 Ujwal Basnet
- 22 Email: ujwalbpkihs@gmail.com
- 23 Shreya Dhungana
- 24 Email: shreyadhungana@gmail.com
- 25 Durga Neupane
- 26 Email: neupanedurga26@gmail.com
- 27
- 28
- 29
- 30

31 Abstract

32

33 Introduction:

34 The relationship between COVID-19 vaccination and Coronavirus disease severity and outcomes

- 35 remain topics of significant interest. This cross-sectional study done among COVID-19 patients
- 36 admitted to the High-dependency unit of a tertiary hospital in Eastern Nepal aimed to assess the
- 37 association between vaccination status, prior infection, and disease outcomes, and the modification
- 38 of these associations by the presence or absence of comorbidities.
- 39

40 Methodology:

- 41 Demographic and clinical data were collected from 102 COVID-19 patients admitted to the High-
- 42 Dependency Unit of Mechi Zonal Hospital, including information on vaccination status,
- 43 comorbidities, disease severity, and outcomes. Statistical analysis, including chi-square tests and
- 44 Fisher's exact tests, was performed to examine the associations.
- 45

46 **Results:**

47 Among the study participants, 49% had received at least one dose of COVID-19 vaccine.

- 48 Vaccinated individuals had a significantly lower rate of severe disease compared to non-vaccinated 49 individuals ($\chi^2=10.05$, p=0.002). Recovery and mortality rates did not differ significantly between
- individuals (χ^2 =10.05, p=0.002). Recovery and mortality rates did not differ significantly between the two groups (χ^2 =1.008, p=0.315). However, when stratified by comorbidities, vaccinated
- 50 the two groups (χ -1.008, p=0.515). However, when stratmed by comorbidities, vaccinated 51 individuals with comorbidities had higher recovery rates compared to non-vaccinated individuals
- 52 (85.29% vaccinated vs. 25.00% non-vaccinated, Fisher's exact test p=0.024). Vaccinated
- 53 individuals, both with and without comorbidities, had lower rates of severe disease compared to
- 54 non-vaccinated individuals. However, the association was found to be significant only in
- 55 individuals with comorbidities (12.50% vaccinated without comorbidities vs. 47.92% non-
- vaccinated, p=0.017; 23.53% vaccinated with comorbidities vs. 75.00% non-vaccinated, p=0.065).
- 57

58 Conclusion:

59 Our findings suggest that COVID-19 vaccination is associated with a reduced risk of severe 60 disease among individuals with or without comorbidities and decreased risk of mortality among

- 61 those with comorbidities. However, larger studies are needed to validate these findings and further
- 62 explore the impact of vaccination on disease outcomes. These findings support the ongoing efforts
- 63 to promote COVID-19 vaccination as a crucial public health intervention.
- 64 Keywords: COVID-19, vaccination status, comorbidities, disease severity, outcomes.
- 65
- 66
- 67
- 68

69 Introduction

70

The novel coronavirus disease, COVID-19, has imposed significant challenge for public health officials and healthcare providers. According to the World Health Organization, over 6.9 million

deaths have been implicated to COVID-19.¹ Many questions are vet to be explored and answered

regarding the virus, SARS-CoV-2. Much is understood about the viral infection and the modes of

- 74 regarding the virus, SARS-Cov-2. Which is understood about the virus infection and the modes of 75 transmission, but the timing, magnitude, and longevity of humoral immunity after natural infection
- 76 and vaccination are still a subject of study. $^{2-4}$
- 77

A breakthrough infection is an infection with a virus, bacterium or other germ after you have been vaccinated.⁵ Vaccine breakthrough infections are expected. COVID-19 vaccines are effective at

80 preventing most infections. However, like other vaccines, they are not 100% effective.⁶ Fully

- 81 vaccinated people with a vaccine breakthrough infection are less likely to develop serious illness
- 82 than those who are unvaccinated and get COVID-19.⁶
- 83

84 For epidemiologic purposes, severe Covid-19 in adults is defined as dyspnea, a respiratory rate of

30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2:FIO2) of less than 300 mm

Hg, or infiltrates in more than 50% of the lung field.^{7,8}

88

89 The recommended dosage of AstraZeneca (ChAdOx1-S [recombinant] vaccine) is two doses given

90 intramuscularly (0.5ml each) with an interval of 8 to 12 weeks.^{9,10} WHO recommends two doses

91 of Janssen Ad26.COV2.S COVID-19 vaccine. The second dose should be given 2-6 months after

92 the first dose.¹¹ The recommended dose of Sinopharm COVID-19 vaccine (Verocell) is 2 doses

93 (0.5 mL each) at a recommended interval of 3 to 4 weeks.¹²

94

We conducted this study to try and attempt to answer few questions – first, among the hospitalized participants, whether there was a significant difference in disease severity and mortality among

97 the vaccinated and non-vaccinated participants; second, whether there was a significant difference

98 between disease severity and mortality among reinfected individuals and new cases.

99

In summary, the aim of this study is to evaluate the effectiveness of vaccination in preventing severe disease and mortality in individuals with and without comorbidities. We aim to assess the impact of vaccination on the adverse outcomes, including severe disease and mortality by analyzing the vaccination status of participants who experienced such outcomes. We believe that the findings of this study will contribute to our understanding of the role of vaccination in mitigating the severity of illness and reducing mortality, particularly in individuals with underlying comorbidities. This knowledge can inform public health strategies and guide decision-making

107 regarding vaccination recommendations for vulnerable populations.

109 Material and Methods

110

111 The required information and data for this study were collected from various sources like PubMed,

112 World Health Organization (WHO), Johns Hopkins Medicine, Center for Disease Control (CDC)

113 and the New England Journal of Medicine (NEJM). The key terms used were COVID-19,

114 coronavirus, SARS-CoV-2, breakthrough infection, vaccination, and severe COVID-19.

115

116 A descriptive cross-sectional study was carried out among the cases of COVID-19 admitted in the

117 High Dependency Unit (HDU) of Mechi Zonal Hospital, Nepal for two months (January 26th to

118 March 26th, 2022). The phone number of the participants or their guardians were obtained from 119 the registry of the HDU. The participants or their guardians (in case of the death of the participant)

120 were contacted via telephone and the information sheet was read out to them in the Nepali language

120 were contacted via telephone and the information sneet was read out to them in the Nepali language (which they preferred). The participants (or their guardians, in case of the participant's death) who

(which they preferred). The participants (or their guardians, in case of the participant)provided verbal consent for the study were enrolled in the study.

123

124 The ethical clearance was obtained from the Nepal Health Research Council on April 17th, 2022.

125 The study was started on June 1st, 2022, and the data collection was completed on June 18th, 2022.

126 We used a pre-tested questionnaire for conducting this study. With the help of the questionnaire,

127 data were collected from the participants or their guardians. The information about the hospital

128 stay of the participants was obtained from the medical records section of the hospital.

129

130 The data was collected, tabulated, and statistically analyzed using Statistical Package for Social

131 Sciences version 25.

133 **Results**

During the study period, there were a total of 120 cases of COVID-19 admitted in the High Dependency Unit of Mechi Zonal Hospital, Nepal. 18 participants or their guardians either declined to participate or couldn't be contacted. So, we collected the data from 102 participants or their guardians for the study.

138

Among the study participants, 52% were male and 48% were female. The mean age of our study population was 48.34 ± 26.15 years with a minimum age of 11 days and a maximum age of 96 years. The age category with the highest representation was 18-59 years, comprising 43.14% of

- 142 the participants (Figure 1).
- 143

Among the study participants, 4.9% (n=5) had a history of prior documented infection with COVID-19 (Figure 2).

146

147 The majority of the participants of the age group 18-59 years (56.82%) and those aged 60 years 148 and greater (60.98%) were vaccinated. No participants below 18 years of age were vaccinated 149 (Figure 3).

- 149 (Figure
- 150
- 151

Among the study participants, 49% (n=50) had received at least one dose of a COVID-19 vaccine

while 51% (n=52) had not. Among the vaccinated participants, the majority of them (46%) had

- received AstraZeneca (ChAdOx1-S [recombinant]) vaccine followed by Sinopharm COVID-19
- vaccine (Verocell) (34%) and Janssen Ad26.COV2.S COVID-19 vaccine (20%) (Figure 4).
- 156

157

Among the vaccinated participants, 50% (n=25) had received their last dose of vaccination within 3 months of admission and an equal percentage of participants had received their last dose greater

159 3 months of admission and an equal percenta160 than 3 months prior to admission (Figure 5).

161

162 Among the vaccinated participants, 46% (n=23) had received only a single dose, while 54% (n=27)

had received 2 doses of the vaccines (Figure 6). All of the participants who had received Janssen

164 Ad26.COV2.S COVID-19 vaccine had received only one dose whereas 69.57% (n=16) of

the participants receiving the AstraZeneca (ChAdOx1-S [recombinant]) vaccine (n=23) and 64.71% (n=11) of the participants receiving Sinopharm COVID-19 vaccine (Verocell) had

167 received two doses of the vaccine (Figure 7).

168

- 170
- 171
- 172

173 When the participants received two doses of the vaccine, the majority of them had not followed

the dosing interval recommended by WHO. Only 11.76% (n=2) of participants receiving the

175 Sinopharm COVID-19 vaccine (Verocell) and 17.39% (n=4) receiving the AstraZeneca

176 (ChAdOx1-S [recombinant] vaccine) had adhered to the dosing interval recommended by the
 177 World Health Organization (WHO) (Table 1). Overall, only 22.22% of participants (n=6) had

received the vaccines as per the WHO recommended interval, while 77.78% of participants

179 (n=21) had not (Figure 8).

180

181 Association Analysis

182 Vaccinated participants (n=50) had a significantly lower rate of severe disease compared to non-

183 vaccinated participants (n=52) (20.00% vaccinated vs. 50.00% non-vaccinated, χ^2 =10.05,

184 p=0.002) (Figure 9).

185 We examined the outcomes of participants in terms of recovery and mortality rates in our study.

186 Among the vaccinated participants (n=50), 44 (88.00%) recovered, while 6 (12.00%) expired.

187 Similarly, among the unvaccinated individuals (n=52), 42 (80.77%) recovered, and 10 (19.23%)

188 expired (Table 2, Figure 10). No statistically significant difference was observed in recovery and

189 mortality rates between the vaccinated and unvaccinated groups ($\chi^2=1.008$, p=0.315).

190

191

We analyzed the association between severity and vaccination status as well as between outcome and vaccination status among patients who received different types of vaccines (Table 3). There was no significant difference between severe and non-severe disease in the participants who received different types of vaccines (Fisher's exact test, p = 0.296). Also, there was no significant

196 association between different vaccine types and outcome (Fisher's exact test, p = 0.740)

197

Among the vaccinated participants receiving two doses of the vaccine, we analyzed the association between adherence to recommended dosing intervals and severity of infection or mortality (Table 4). There were no statistically significant associations between participants who adhered to the recommended dosing interval and who did not in terms of severity (p = 0.56) or mortality (p = 2021.00).

203

Participants who received their last dose of vaccination within 3 months of admission (n=25) had a significantly lower rate of severe disease compared to those who received their last vaccine

dose more than 3 months prior (8% vaccinated within 3 months vs. 24% vaccinated more than 3 months, χ^2 =4.500, p=0.034). Additionally, all participants who received their last vaccine dose within 3 months recovered, while 24% of those who received their last dose more than 3 months ago expired (Table 5). The association was found to be statistically significant (p=0.022, Fisher's exact test).

211

We stratified the severity and outcome in vaccinated and non-vaccinated participants in terms of whether or not they had any comorbidities (Table 6). The major co-morbidities noted in our study participants were hypertension, diabetes mellitus, and chronic obstructive pulmonary disease.

215 Vaccinated participants with or without comorbidities had significantly lower rates of severe 216 disease compared to non-vaccinated participants (Fisher's exact test, p = 0.065 for participants

without comorbidities; $\chi^2 = 6.323$, p = 0.017 for participants with comorbidities).

218

219 Vaccinated participants with comorbidities had significantly lower mortality rate (14.71%)

220 compared to non-vaccinated participants (75.00%), indicating an approximately 5-fold higher

221 mortality rate among the non-vaccinated group (Fisher's exact test, p=0.024).

222 With comorbidities absent, we found no statistical significance through Fisher's exact test 223 (p=0.667) between the mortality rates of vaccinated and unvaccinated groups.

224

Also, we stratified the severity of infections and outcomes according to age factor (Table 7). Statistical analysis showed no significant difference between severity and vaccination status among participants aged 60 years and above (Fisher's exact test, p = 0.287). But there was a significant association between severity and vaccination status among the participants of the age group 18-59 years (χ^2 =8.481, p = 0.004). There was no significant difference in outcome and vaccination status among the participants of the age group 18-59 years (Fisher's exact test, p =0.210) and age group >=60 years (Fisher's exact test, p = 1.00)

232

233 We analyzed the association between prior infection and severity as well as outcome of current

- 234 infection (Table 8). Fisher's exact test failed to reveal a significant association between prior
- infection and current infection severity (p = 0.158) or outcome (p = 1.0).

236

237

238

240 **Discussion**

241 The purpose of this study was to look into the relationship between vaccination status, re-infection, 242 and clinical outcomes among patients admitted to the COVID High Dependency Unit (HDU). We 243 looked into things like the type of COVID-19 vaccine used, the number of vaccine doses given, 244 adherence to recommended dosing intervals, time since vaccination, and the effect of vaccination 245 on severity and outcome. Furthermore, we investigated the impact of comorbidities and prior 246 infection on disease severity and outcome. We believe that this study will contribute to the 247 understanding of COVID-19 vaccine effectiveness by guiding clinical decision-making and public 248 health interventions. We compare our findings to the existing literature, identify limitations, and 249 suggest future research directions.

- The gender distribution among participants in our study was relatively balanced, with 52% male and 48% female. This gender distribution reflects our study population's inclusion of both males and females, allowing for a more representative analysis. In terms of vaccination status, we found that 49% of participants had received at least one dose of COVID-19 vaccine, while 51% had not received any. This distribution sheds light on vaccination coverage in the study population, indicating that a sizable proportion of people had not yet received any COVID-19 vaccine at that time. This finding may have implications for how the results of the study on the relationship
- between vaccination status and the severity or outcome of the current infection are interpreted.
- Our finding showed that vaccination with the COVID-19 vaccine is associated with a significantly lower risk of severe disease is consistent with the studies in the past which investigated the association between vaccination and disease severity.^{13–15} However, unlike these studies, our study failed to demonstrate a significant relationship between vaccination status and the outcome (recovery or death).
- 263 One study by Bernal et al. showed that one dose of either BNT162b2 or ChAdOx1-S offered 264 protection against severe disease for > 6 weeks. Our study finding is in line with this finding as it 265 showed that the vaccinated patients who were infected with COVID-19 within 3 months of 266 vaccination had a significantly lower risk of severe disease and mortality.¹⁶
- Our study had some limitations. First, a relatively small sample size in our study may limit the generalizability of the findings to broader populations. Second, the study design was crosssectional, which limits our ability to establish causal relationships. Longitudinal studies or randomized controlled trials would provide stronger evidence of the impact of vaccination and comorbidities on disease outcomes. Additionally, there may have been confounding factors that were not accounted for in our analysis, such as socioeconomic status or access to healthcare. These factors could potentially influence both vaccination status and disease outcomes.
- Lastly, our study focused on a specific population or setting, which may limit the generalizability of the findings to other regions or healthcare settings. Variations in vaccination rates, healthcare infrastructure, and population characteristics could affect the observed associations.
- 277 Despite these limitations, our study contributes valuable insights into the association between 278 vaccination status, comorbidities, and disease outcomes in COVID-19 patients. Further research

279 with larger sample sizes, more rigorous study designs, and diverse populations is warranted to

280 build upon our findings and provide a more comprehensive understanding of these relationships.

281 Conclusion:

Our findings suggest that COVID-19 vaccination is associated with a reduced risk of severe disease among individuals with or without comorbidities and decreased risk of mortality among those with comorbidities. However, larger studies are needed to validate these findings and further explore the impact of vaccination on disease outcomes. These findings support the ongoing efforts to promote COVID-19 vaccination as a crucial public health intervention.

287

288 CONFLICT OF INTEREST

- 289 The authors declare that the research was conducted in the absence of any commercial or financial
- 290 relationship that could be construed as a potential conflict of interest.

291 FUNDING SOURCES

292 None

293 ACKNOWLEDGEMENT

We thank all the patients participating in this study.

295 ETHICAL APPROVAL

296 The study protocol (Code no. 48/2022 P) was approved by Nepal Health Research Council.

297 CONSENT FOR PUBLICATION

- 298 Written informed consent was obtained from the patients for publication of this original article. A
- 299 copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

300 AUTHORS CONTRIBUTION

- 301 All the authors contributed equally to writing and preparing the manuscript. The final version of
- 302 the article is approved by all authors.

303 RESEARCH REGISTRATION

304 No new surgical techniques or new equipment/technology was used.

305 PROVENANCE AND PEER REVIEW


306 Not commissioned, externally peer reviewed.


307 DATA AVAILABILITY STATEMENT


- 308 Datasets generated during and/or analyzed during the current study are available upon reasonable request.
- 309
- 310 References
- WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
 With Vaccination Data. Accessed June 4, 2023. https://covid19.who.int/
- Kellam P, Barclay W. The dynamics of humoral immune responses following SARS CoV-2 infection and the potential for reinfection. *J Gen Virol*. 2020;101(8):791-797.
 doi:10.1099/JGV.0.001439
- Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science (1979)*.
 2020;368(6493):860-868. doi:10.1126/SCIENCE.ABB5793/SUPPL FILE/PAPV4.PDF
- Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune
 response of patients with severe acute respiratory syndrome. *J Infect Dis*.
 2006;193(6):792-795. doi:10.1086/500469
- Breakthrough Infections: Coronavirus After Vaccination | Johns Hopkins Medicine.
 Accessed June 4, 2023. https://www.hopkinsmedicine.org/health/conditions-anddiseases/coronavirus/breakthrough-infections-coronavirus-after-vaccination
- Monitoring COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status | CDC.
 Accessed June 4, 2023. https://www.cdc.gov/coronavirus/2019 ncov/vaccines/effectiveness/monitoring.html?CDC_AA_refVal=https%3A%2F%2Fwww.
 cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Feffectiveness%2Fwhy-measure effectiveness%2Fbreakthrough-cases.html
- 330 7. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *New England Journal of Medicine*.
 331 2020;383(25):2451-2460.
- doi:10.1056/NEJMCP2009575/SUPPL_FILE/NEJMCP2009575_DISCLOSURES.PDF
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
 From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239 1242. doi:10.1001/JAMA.2020.2648
- 337 9. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what
 338 you need to know. Accessed June 6, 2023. https://www.who.int/news-room/feature339 stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
- 340 10. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the
 341 influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1

342 343		nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>The Lancet</i> . 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
344 345 346	11.	The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. Accessed June 6, 2023. https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know
347 348 349	12.	The Sinopharm COVID-19 vaccine: What you need to know. Accessed June 6, 2023. https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
350 351 352	13.	Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. <i>JAMA</i> . 2021;326(20):2043-2054. doi:10.1001/JAMA.2021.19499
353 354 355	14.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>N Engl J Med.</i> 2020;383(27):2603-2615. doi:10.1056/NEJMOA2034577
356 357	15.	Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>N Engl J Med</i> . 2021;384(5):403-416. doi:10.1056/NEJMOA2035389
358 359 360 361	16.	Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ</i> . 2021;373. doi:10.1136/BMJ.N1088
362		
363		
364		
365		
366		
367		
368		
369		
370		
371		
372		
373		
374		


375 Graphs and tables




















493 Tables

Name of the vaccine	Single dose	Received two	doses of the vac	cine
Janssen Ad26.COV2.S	10	0		
COVID-19	(100%)			
			RDI*	NRDI
Sinopharm COVID-19	6	11		
vaccine (Verocell)	(35.29%)	(64.71%)	2	9
			(11.76%)	(52.94
			RDI*	NRDI
AstraZeneca (ChAdOx1-S	7	16		
[recombinant] vaccine)	(30.43%)	(69.57%)	4	12
			(17.39%)	(52.17
*: As per recommended dosin **: Not as per recommended Table 1: Patients who received o	dosing interval	the vaccines		

494

495

Severity Outcome Recovered Non-severe Severe Expired disease disease Vaccinated 40 (80.00%) 10 (20.00%) 44 (88.00%) 6 (12.00%) Non-26 (50.00%) 26 (50.00%) 42 (80.77%) 10 (19.23%) vaccinated Table 2: Outcomes among the vaccinated and non-vaccinated patients

498	
-----	--

	S	everity	Outcome		
	Non-severe disease	Severe disease	Recovered	Expired	
Janssen	4	6	8	2	
Ad26.COV2.S	(40.00%)	(60.00%)	(80.00%)	(20.00%)	
COVID-19					
Sinopharm	14	3	15	2	
COVID-19	(82.35%)	(17.65%)	(88.24%)	(11.76%)	
vaccine	. ,				
(Verocell)					
AstraZeneca	20	3	21	2	
(ChAdOx1-S	(86.96%)	(13.04%)	(91.30%)	(8.70%)	
[recombinant]	. ,	```'	` '	~ /	

Table 3: Association between different types of vaccines with severity and mortality of disease

	Seve	rity	Outc	ome
	Non-severe	Severe	Recovered	Expired
	disease	disease		
commended	6	0	6	0
ing interval	(100%)		(100%)	
Not as per	16	5	18	3
commended	(76.19%)	(23.81%)	(85.71%)	(14.29%)
sing interval	````		. , ,	. ,

Table 4: Severity and outcome among the patients receiving two doses of vaccines who were and were not vaccinated with dosing intervals as per WHO recommendation.

	Sev	verity	Outcome		
Last vaccination	Non-severe disease	Severe disease	Recovered	Expired	
<=3 months	23 (92.00%)	2 (8.00%)	25 (100.00%)	0	
>3 months	17 (68.00%)	8 (32.00%)	19 (76.00%)	6 (24.00%)	

Table 5: Severity and outcome among patients receiving last dose of their vaccine within 3 months and greater than 3 months.

		Seve	erity	Outc	ome
		Non- severe disease	Severe disease	Recovered	Expired
Comorbidities	Vaccinate	14	2	15	1
absent	d	(87.50%)	(12.50%)	(73.75%)	(6.25%)
	Non-	25	23	41	7
	vaccinated	(52.08%)	(47.92%)	(85.42%)	(14.58%)
omorbidities	Vaccinate	26	8	29	5
resent	d	(76.47%)	(23.53%)	(85.29%)	(14.71%)
	Non-	1	3	1	3
	vaccinated	(25.00%)	(75.00%)	(25.00%)	(75.00%)

Table 6: Severity of infection and outcome among vaccinated and non-vaccinated patients

Age category	Vaccination status	Non-severe disease	Severe disease	Recovered	Expired
<18 years	Vaccinated	0	0	0	0
	Non-	9	8	14	3
	vaccinated	(52.9%)	(47.1%)	(82.35%)	(17.65%)
18-59 years	Vaccinated	20	5	23	2
-		(80.00%)	(20.00%)	(92.00%)	(8.00%)
	Unvaccinated	7	12	14	5
		(36.84%)	(63.16%)	(73.68%)	(26.32%)
>=60 years	Vaccinated	20	5	21	4
-		(80.00%)	(20.00%)	(84.00%)	(16.00%)
	Unvaccinated	10	6	14	2
		(62.50%)	(37.50%)	(87.50%)	(12.50%)

Table 7: Severity and outcome of COVID-19 infections among vaccinated and non-vaccinated groups according to different age category

514

515

	S	Severity	Οι	utcome
	Non-Severe	Severe disease	Recovered	Expired
	disease			
Prior infection	5	0	5	0
with COVID-19	(100%)		(100%)	
No Prior infection	61	36	81	16
with COVID-19	(62.89%)	(37.11%)	(83.51%)	(16.49%)

Table 8: Prior infection and severity or outcome of current infection